NCT05883956: A trial that was reported late by Otsuka Australia Pharmaceutical Pty Ltd
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05883956 |
|---|---|
| Title | A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 30, 2023 |
| Completion date | April 30, 2025 |
| Required reporting date | April 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 18, 2024 |
| Days late | None |